{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:33:24Z","timestamp":1792456404898,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40268-025-00509-6","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T10:31:35Z","timestamp":1748169095000},"page":"153-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate"],"prefix":"10.1007","volume":"25","author":[{"given":"Derek E.","family":"Murrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin C.","family":"Kennard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Cluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Moorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Duffourc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-3756","authenticated-orcid":false,"given":"Sam","family":"Harirforoosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"key":"509_CR1","unstructured":"World Health Organization. HIV\/AIDS. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids"},{"key":"509_CR2","unstructured":"U.S. Department of Health and Human Services. HIV Treatment. Available from: https:\/\/www.hiv.gov\/"},{"issue":"3","key":"509_CR3","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.xphs.2016.12.003","volume":"106","author":"ME Watkins","year":"2017","unstructured":"Watkins ME, Wring S, Randolph R, Park S, Powell K, Lutz L, et al. Development of a novel formulation that improves preclinical bioavailability of tenofovir disoproxil fumarate. J Pharm Sci. 2017;106(3):906\u201319.","journal-title":"J Pharm Sci"},{"issue":"10","key":"509_CR4","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1681\/ASN.2012080857","volume":"24","author":"J Tourret","year":"2013","unstructured":"Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013;24(10):1519\u201327.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"509_CR5","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/infdis\/jiaa125","volume":"222","author":"B Surial","year":"2020","unstructured":"Surial B, Ledergerber B, Calmy A, Cavassini M, Gunthard HF, Kovari H, et al. Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study. J Infect Dis. 2020;222(4):637\u201345.","journal-title":"J Infect Dis"},{"issue":"4","key":"509_CR6","first-page":"526","volume":"29","author":"G Di Perri","year":"2021","unstructured":"Di Perri G. Tenofovir alafenamide (TAF) clinical pharmacology. Infez Med. 2021;29(4):526\u20139.","journal-title":"Infez Med"},{"issue":"5","key":"509_CR7","first-page":"904","volume":"19","author":"DE Murrell","year":"2015","unstructured":"Murrell DE, Moorman JP, Harirforoosh S. Stribild: a review of component characteristics and combination drug efficacy. Eur Rev Med Pharmacol Sci. 2015;19(5):904\u201314.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"509_CR8","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1128\/AAC.00128-15","volume":"59","author":"E Murakami","year":"2015","unstructured":"Murakami E, Wang T, Park Y, Hao J, Lepist EI, Babusis D, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother. 2015;59(6):3563\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"509_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","volume":"62","author":"K Agarwal","year":"2015","unstructured":"Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015;62(3):533\u201340.","journal-title":"J Hepatol"},{"issue":"5","key":"509_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","volume":"5","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5(5):441\u201353.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"509_CR11","volume":"2011","author":"B Fernandez-Fernandez","year":"2011","unstructured":"Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD, Izquierdo MC, Poveda J, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011: 354908.","journal-title":"AIDS Res Treat."},{"issue":"11","key":"509_CR12","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1177\/1060028016660812","volume":"50","author":"AK Gibson","year":"2016","unstructured":"Gibson AK, Shah BM, Nambiar PH, Schafer JJ. Tenofovir alafenamide. Ann Pharmacother. 2016;50(11):942\u201352.","journal-title":"Ann Pharmacother"},{"key":"509_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","volume":"125","author":"AS Ray","year":"2016","unstructured":"Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res. 2016;125:63\u201370.","journal-title":"Antiviral Res"},{"issue":"6","key":"509_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1345\/aph.1C388","volume":"37","author":"SA Grim","year":"2003","unstructured":"Grim SA, Romanelli F. Tenofovir disoproxil fumarate. Ann Pharmacother. 2003;37(6):849\u201359.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"509_CR15","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1128\/AAC.01096-13","volume":"57","author":"PL Havens","year":"2013","unstructured":"Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, et al. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 2013;57(11):5619\u201328.","journal-title":"Antimicrob Agents Chemother"},{"key":"509_CR16","first-page":"1315","volume":"14","author":"X Li","year":"2021","unstructured":"Li X, Tan XY, Cui XJ, Yang M, Chen C, Chen XY. Pharmacokinetics of tenofovir alafenamide fumarate and tenofovir in the chinese people: effects of non-genetic factors and genetic variations. Pharmgenomics Pers Med. 2021;14:1315\u201329.","journal-title":"Pharmgenomics Pers Med."},{"issue":"4","key":"509_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/cid\/ciab1010","volume":"75","author":"VE Bukkems","year":"2022","unstructured":"Bukkems VE, Necsoi C, Hidalgo Tenorio C, Garcia C, Alba Alejandre I, Weiss F, et al. Tenofovir alafenamide plasma concentrations are reduced in pregnant women living with human immunodeficiency virus (HIV): data from the PANNA network. Clin Infect Dis. 2022;75(4):623\u20139.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"509_CR18","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1086\/378068","volume":"37","author":"JE Gallant","year":"2003","unstructured":"Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. 2003;37(7):944\u201350.","journal-title":"Clin Infect Dis"},{"key":"509_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ijid.2020.06.037","volume":"97","author":"TR Cressey","year":"2020","unstructured":"Cressey TR, Siriprakaisil O, Kubiak RW, Klinbuayaem V, Sukrakanchana PO, Quame-Amaglo J, et al. Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. Int J Infect Dis. 2020;97:365\u201370.","journal-title":"Int J Infect Dis"},{"issue":"7","key":"509_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3851\/IMP2770","volume":"19","author":"RA Bam","year":"2014","unstructured":"Bam RA, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther. 2014;19(7):687\u201392.","journal-title":"Antivir Ther"},{"issue":"3","key":"509_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40261-018-0739-9","volume":"39","author":"DE Murrell","year":"2019","unstructured":"Murrell DE, Cluck DB, Moorman JP, Brown SD, Wang KS, Duffourc MM, et al. HIV integrase inhibitor pharmacogenetics: an exploratory study. Clin Drug Investig. 2019;39(3):285\u201399.","journal-title":"Clin Drug Investig"},{"key":"509_CR22","unstructured":"Line D, Gong L, Giacomini KM, Dhoro M. Tenofovir\/adefovir pathway, pharmacokinetics. 2019; Available from: https:\/\/www.pharmgkb.org\/pathway\/PA155028030"},{"issue":"6","key":"509_CR23","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1128\/AAC.04930-14","volume":"59","author":"K Rungtivasuwan","year":"2015","unstructured":"Rungtivasuwan K, Avihingsanon A, Thammajaruk N, Mitruk S, Burger DM, Ruxrungtham K, et al. Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients. Antimicrob Agents Chemother. 2015;59(6):3240\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"509_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116678","volume":"175","author":"J Cusato","year":"2024","unstructured":"Cusato J, Manca A, Palermiti A, Mula J, Antonucci M, Chiara F, et al. Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact? Biomed Pharmacother. 2024;175: 116678.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"509_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/FPC.0000000000000491","volume":"33","author":"S Mateza","year":"2023","unstructured":"Mateza S, Bradford Y, Maartens G, Sokhela S, Chandiwana NC, Venter WDF, et al. Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans. Pharmacogenet Genomics. 2023;33(5):91\u2013100.","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"509_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3390\/ijms19030855","volume":"19","author":"K Alam","year":"2018","unstructured":"Alam K, Crowe A, Wang X, Zhang P, Ding K, Li L, et al. Regulation of organic anion transporting polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-mediated drug-drug interactions. Int J Mol Sci. 2018;19(3):855.","journal-title":"Int J Mol Sci"},{"issue":"7\u20138","key":"509_CR27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/17425255.2022.2112175","volume":"18","author":"M Yang","year":"2022","unstructured":"Yang M, Xu X. Important roles of transporters in the pharmacokinetics of anti-viral nucleoside\/nucleotide analogs. Expert Opin Drug Metab Toxicol. 2022;18(7\u20138):483\u2013505.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"509_CR28","unstructured":"PharmGKB, Variant Annotations. Available from: https:\/\/www.pharmgkb.org\/chemical\/PA10204\/variantAnnotation"},{"key":"509_CR29","unstructured":"PharmGKB, FDA Drug Label Annotations and PGx Associations. Available from: https:\/\/www.pharmgkb.org\/chemical\/PA10204\/clinicalAnnotation"},{"issue":"2","key":"509_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263\u20135.","journal-title":"Bioinformatics"},{"issue":"2","key":"509_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/bib\/3.2.146","volume":"3","author":"CM Lewis","year":"2002","unstructured":"Lewis CM. Genetic association studies: design, analysis and interpretation. Brief Bioinform. 2002;3(2):146\u201353.","journal-title":"Brief Bioinform"},{"issue":"3","key":"509_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559\u201375.","journal-title":"Am J Hum Genet"},{"key":"509_CR33","unstructured":"American Board of Internal Medicine, Laboratory Test Reference Ranges-January 2025. Available from: https:\/\/www.abim.org\/~\/media\/ABIM%20Public\/Files\/pdf\/exam\/laboratory-reference-ranges.pdf"},{"key":"509_CR34","unstructured":"MedlinePlus. Bethesda (MD): National Library of Medicine (US). Glomerular filtration rate. Available from: https:\/\/medlineplus.gov\/ency\/article\/007305.htm"},{"issue":"12","key":"509_CR35","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1507\/endocrj.EJ20-0203","volume":"67","author":"N Matsuda","year":"2020","unstructured":"Matsuda N, Takasawa K, Ohata Y, Takishima S, Kubota T, Ishihara Y, et al. Potential pathological role of single nucleotide polymorphism (c.787T>C) in alkaline phosphatase (ALPL) for the phenotypes of hypophosphatasia. Endocr J. 2020;67(12):1227\u201332.","journal-title":"Endocr J"},{"issue":"1","key":"509_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.yexmp.2018.01.001","volume":"104","author":"E Larrieta-Carrasco","year":"2018","unstructured":"Larrieta-Carrasco E, Flores YN, Mac\u00edas-Kauffer LR, Ram\u00edrez-Palacios P, Quiterio M, Ram\u00edrez-Salazar EG, et al. Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population. Exp Mol Pathol. 2018;104(1):50\u20138.","journal-title":"Exp Mol Pathol"},{"issue":"5","key":"509_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pctr.0020027","volume":"2","author":"L Peterson","year":"2007","unstructured":"Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2(5): e27.","journal-title":"PLoS Clin Trials"},{"issue":"2","key":"509_CR38","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/FPC.0000000000000110","volume":"25","author":"A Dahlin","year":"2015","unstructured":"Dahlin A, Wittwer M, de la Cruz M, Woo JM, Bam R, Scharen-Guivel V, et al. A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenet Genomics. 2015;25(2):82\u201392.","journal-title":"Pharmacogenet Genomics"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-025-00509-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:55:20Z","timestamp":1750694120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-025-00509-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["509"],"URL":"https:\/\/doi.org\/10.1007\/s40268-025-00509-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"29 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was partly funded by a Research and Development Committee Interdisciplinary Grant and a Graduate Studies Student Research Grant from East Tennessee State","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All study procedures were conducted in accordance with the 1964 Helsinki Declaration (and its amendments). The study was approved by the East Tennessee State University\/Veterans Affairs Medical Campus Institutional Review Board (IRB no. 1214.4sw).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from study participants in the presence of at least one investigator and witness.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"D.E.M. designed and implemented the study, performed the experiments, analyzed the data, and wrote the manuscript; B.C.K. analyzed the data and wrote the manuscript; M.E.B. analyzed the data and wrote the manuscript; D.B.C. designed and implemented the study and wrote the manuscript; J.P.M. designed and implemented the study and wrote the manuscript; S.D.B. performed the experiments, analyzed the data, and wrote the manuscript; K.W. designed the study, analyzed the data, and wrote the manuscript; M.M.D. designed the study and wrote the manuscript; S.H. designed and implemented the study, performed the experiments, analyzed the data, and wrote the manuscript. All authors reviewed and approved the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}